<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> comprises biologically and clinically distinct diseases the pathogenesis of which is associated with genetic lesions affecting oncogenes and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-suppressor genes </plain></SENT>
<SENT sid="1" pm="."><plain>We report here that the two most common types--follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>--harbour frequent structural alterations inactivating CREBBP and, more rarely, EP300, two highly related <z:chebi fb="0" ids="15358">histone</z:chebi> and non-<z:chebi fb="0" ids="15358">histone</z:chebi> acetyltransferases (HATs) that act as transcriptional co-activators in multiple signalling pathways </plain></SENT>
<SENT sid="2" pm="."><plain>Overall, about 39% of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 41% of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases display genomic deletions and/or <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> that remove or inactivate the HAT coding domain of these two genes </plain></SENT>
<SENT sid="3" pm="."><plain>These lesions usually affect one allele, suggesting that reduction in HAT dosage is important for <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We demonstrate specific defects in acetylation-mediated inactivation of the BCL6 oncoprotein and activation of the p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor </plain></SENT>
<SENT sid="5" pm="."><plain>These results identify CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms </plain></SENT>
</text></document>